| Literature DB >> 21228798 |
Abstract
The goal of a bundled payment policy for dialysis is to decrease overall expenditures and shift financial risk from the payer to the provider. The primary target for cost reduction is invariably erythropoiesis-stimulating agents (ESAs), because of their large costs and potential for dose sparing. Japan succeeded in reducing ESA doses and maintaining stable hemoglobin levels through modest increases in intravenous iron administration. Dialysis providers in the United States have this and other strategies available.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21228798 DOI： 10.1038/ki.2010.459
Source DB: PubMed Journal: Kidney Int ISSN： 0085-2538 Impact factor: 10.612